Short Communication

Rapamycin Extends Maximal Lifespan in Cancer-Prone Mice

Vladimir N. Anisimov,* Mark A. Zabezhinski,*
Irina G. Popovich,* Tatiana S. Piskunova,*
Anna V. Semenchchenko,* Margarita L. Tyndyk,*
Maria N. Yurova,* Marina P. Antoch,[†]
and Mikhail V. Blagosklonny[‡]

From the Department of Carcinogenesis and Oncogerontology,*
N.N. Petrov Research Institute of Oncology, St. Petersburg,
Russia; and the Departments of Molecular and Cellular
Biology,[†] and Cell Stress Biology,[‡] Roswell Park Cancer
Institute, Buffalo, New York

Aging is associated with obesity and cancer. Calorie restriction both slows down aging and delays cancer. Evidence has emerged that the nutrient-sensing mammalian target of rapamycin (mTOR) pathway is involved in cellular and organismal aging. Here we show that the mTOR inhibitor rapamycin prevents age-related weight gain, decreases rate of aging, increases lifespan, and suppresses carcinogenesis in transgenic HER-2/neu cancer-prone mice. Rapamycin dramatically delayed tumor onset as well as decreased the number of tumors per animal and tumor size. We suggest that, by slowing down organismal aging, rapamycin delays cancer. (Am J Pathol 2010, 176:2092–2097; DOI: 10.2353/ajpath.2010.091050)

Astonishing discoveries in model organisms indicate that lifespan is genetically controlled.¹ In particular, the nutrient-sensing target of rapamycin (TOR) pathway is involved in both mammalian cell senescence² and aging in diverse organisms from worms to mammals.^{3–6} In mammals, TOR (mTOR) controls cell growth and metabolism in response to nutrients (eg, amino acids), insulin, and growth factors such as IGF-1.⁷ Calorie restriction (CR) deactivates mTOR in mice.⁸ Not surprisingly, CR extends lifespan in most species including rodents and primates.^{9,10} Furthermore, the TOR inhibitor rapamycin decelerates senescence in both yeast¹¹ and mammalian cells.¹² Based on these findings it was suggested that rapamycin, a clinically approved drug, is an antiaging drug.¹³ Recently it has been demonstrated that rapamycin

in fact extends lifespan in mice.¹⁴ However, its effect on longevity of cancer-prone mice has not been addressed. There are several lines of evidence that suggest that suppression of organismal aging may delay carcinogenesis. Thus, cancer is an age-related disease, and the incidence of cancer increases with age in both humans and animals.^{15,16} Consistently, carcinogenesis is delayed in slowly aging Ames dwarf mice.^{17,18} Cancer is often associated with age-related obesity and metabolic syndrome,¹⁹ and calorie restriction affects both the process of aging (by slowing it down) and carcinogenesis (by delaying the tumor onset in normal and cancer-prone mice^{20,21}). Interestingly, centenarians, people who age slowly, are endowed with a peculiar resistance to cancer.²² Therefore it is reasonable to hypothesize that by slowing down aging rapamycin could delay cancer. Our data demonstrate that rapamycin not only extends lifespan but also significantly delays the onset of spontaneous carcinogenesis in cancer-prone HER-2/neu transgenic mice.

Materials and Methods

Animals and Experimental Design

Homozygous FVB/N HER-2/neu transgenic mice originally obtained from Charles River (Hollister, CA) by the Italian National Research Center for Aging (INRCA) were housed and bred in the Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology. Mice received standard laboratory chow and tap water *ad libitum*.^{23,24} All studies were conducted in

Supported in part by NIH grant CA102522 (to M.P.A.).

Accepted for publication December 8, 2009.

Supplemental material for this article can be found on <http://ajp.amjpathol.org>.

Address reprint requests to Vladimir N. Anisimov, M.D., Ph.D., DSc., Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, Leningradskaya Str. 68, Pesochny-2, St. Petersburg 197758 Russia, or Mikhail V. Blagosklonny, M.D., Ph.D., Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3-312, Elm and Carlton Streets, Buffalo, NY 14263. E-mail: aging@mail.ru or blagosklonny@oncotarget.com.

accordance with the ethical standards and according to national and international guidelines and have been approved by the authors' institutional review board.

Longevity Study

Fifty-eight 2-month-old female FVB/N HER-2/neu mice were randomly divided into two groups. The first group of animals received 1.5 mg/kg rapamycin (LC Laboratories, Woburn, MA) subcutaneously (s.c.) 3 times a week for a period of 2 weeks followed by 2-week intervals without rapamycin. Mice in the second group received s.c. 0.1 ml of solvent without rapamycin and served as a control. Rapamycin was dissolved in 95% ethanol and then diluted with apyrogenic sterile water to a final concentration of 38 μ g in 0.1 ml of 2% ethanol.

Once a week all mice were palpated for detection of mammary tumors appearance. The localization and the size of tumors were registered. The neoplastic masses were measured with a caliper, and progressively growing masses of >3 mm in mean diameter were regarded as tumors. The mean number of palpable mammary carcinomas per mouse was calculated as the cumulative number of tumors per total number of tumor-bearing mice. Animals were weighed once a month and were observed throughout their lifespan.^{23,24}

Pathomorphological Examination

All animals were autopsied. All tumors, as well as the tissues and organs with suspected tumor development, were excised, fixed in 10% buffered formalin, and embedded into paraffin. Five- μ m histological sections were stained with hematoxylin and eosin and were microscopically examined. Tumors were classified according to International Agency for Research on Cancer recommendations as described.^{23,24}

Statistics

Experimental results were statistically processed by the methods of variation statistics with the use of STATGRAPH statistic program kit as previously described.^{23,24} The significance of the discrepancies was defined according to the Student *t* criterion, Fischer exact method, χ^2 , nonparametric Wilcoxon–Mann–Whitney, and Friedman RM ANOVA on Ranks. Student–Newman–Keuls Method was used for all pairwise multiple comparisons. Correlation coefficient was estimated by Spearman method.^{23,24} Differences in tumor incidence were evaluated by the Mantel–Haenszel log-rank test.

Parameters of Gompertz model were estimated using maximum likelihood method, nonlinear optimization procedure, and self-written code in 'Matlab'; confidence intervals for the parameters were obtained using the bootstrap method (see Anisimov et al^{23,24}).

For experimental group the Cox regression model was used to estimate relative risk of death and tumor development under the treatment compared with the control group: $h(t,z) = h_0(t) \exp(z\beta)$, where $h(t,z)$ and $h_0(t)$ denote the

Figure 1. Effects of rapamycin on age-related weight gain and lifespan of female transgenic HER-2/neu mice. **A:** Effect of rapamycin on body weight in female transgenic HER-2/neu mice. The rapamycin group of animals received 1.5 mg/kg rapamycin three times a week for a period of 2 weeks followed by 2-week intervals without rapamycin. Mice in control group received solvent without rapamycin. Mice were weighed once a month. **B:** Effect of rapamycin on mice survival. Mice were observed throughout their lifespan, and all animals were autopsied. Distributions of lifespan in control and experimental groups were significantly different (log-rank test, $P = 0.00588$). Survival dynamics showed significant differences.

conditional hazard and baseline hazard rates, respectively, β is the unknown parameter for treatment group, and z takes values 0 and 1, being an indicator variable for two samples—the control and treatment group.

Semiparametric model of heterogeneous mortality^{23,24} was used to estimate the influence of the treatment on frailty distribution and baseline hazard.

Mathematical Modeling of the Results

For the rapamycin-treated group (rapamycin group) the Cox regression model was used to estimate relative risk of death and tumor development under the treatment compared with the control group: $h(t,z) = h_0(t) \exp(z\beta)$, where $h(t,z)$ and $h_0(t)$ denote the conditional hazard and baseline hazard rates, respectively, β is the unknown

Table 1. Effect of Rapamycin on Survival Distribution in Female HER-2/neu Mice

Group	Number of survivors at the age of									
	5 mo	6 mo	7 mo	8 mo	9 mo	10 mo	11 mo	12 mo	13 mo	14 mo
Control	28	28	28	28	21	9	4	0	0	0
Rapamycin	30	29	24	23	22	19*	13*	6*	2	0

The difference with the corresponding age in the control group is significant: * $P < 0.01$ (Fischer exact test).

parameter for treatment group, and z takes values 0 and 1, being an indicator variable for two samples—the control and treatment group. For rapamycin group the relative risk of death and the first tumor development is lower ($\exp(\beta) < 1$) compared with control group (see supplemental Table S1 at <http://ajp.amjpathol.org>). All estimated changes in risks were significant, except for the mice with tumors without metastases.

Semiparametric model of heterogeneous mortality was used to compare the control and rapamycin groups to the group of the female mice treated with rapamycin in terms of frailty distribution and baseline hazard.

Survival and mortality rate functions are given by the formulas:

$$S_{\text{rap}}(x) = \left(1 + r\gamma(S_{\text{ic}}(x)^{-\sigma^2} - 1) + r\gamma\sigma^2 \frac{\alpha}{\beta} (\exp(\beta(x - x_0)) - 1) \right)^{-\frac{1}{\gamma\sigma^2}}$$

$$\mu_{\text{rap}}(x) = \frac{r\mu_{\text{ic}}(x) S_{\text{ic}}(x)^{-\sigma^2} + r\alpha \exp(\beta(x - x_0))}{1 + r\gamma(S_{\text{ic}}(x)^{-\sigma^2} - 1) + r\gamma\sigma^2 \frac{\alpha}{\beta} (\exp(\beta(x - x_0)) - 1)}$$

Parameter σ^2 indicates the presence of heterogeneity in the control population.

Differences in the baseline hazard are controlled by parameters α and β . Parameter α reflects permanent (constant) decrease or increase of the baseline hazard compared with the control group, depending on whether α is greater or less than zero. Parameter β describes the amplification or disappearance of the α -effect, according to whether β is greater or less than zero.

Differences in the frailty distribution are controlled by parameters r and γ . Parameter $r < 1$ shows an increase in the average robustness, whereas $r > 1$ indicates an accumulation of frail individuals in the population compared with the control group. Parameter $\gamma \neq 1$ shows an

increase ($\gamma > 1$) or decrease ($\gamma < 1$) in the population heterogeneity.

To compare the survival function for rapamycin-treated female mice to the control group, three specifications of the model were considered. The first one deals only with the differences in the average frailties of the populations ($\alpha = 0$, $r \neq 1$, $\gamma = 1$). With the second specification, differences in the mean of the frailty distributions are accompanied by differences in the baseline hazards ($\alpha \neq 0$, $\beta = 0$, $r \neq 1$, $\gamma = 1$).

The third specification describes differences in survival patterns between the group of interest and the control group as a combination of differences in the baseline hazard and both parameters of the frailty distribution ($\alpha \neq 0$, $\beta \neq 0$, $r \neq 1$, $\gamma \neq 1$). Because these specifications of the model are nested, the likelihood ratio statistics were used to determine which one gives the best fit to the data.

The parameter estimates were obtained using maximum likelihood method, nonlinear optimization procedure, and self-written code in 'Matlab'; confidence intervals for the parameters were obtained using the bootstrap method.

The third specification of the model corresponds to the data better than the others (see supplemental Table S2 at <http://ajp.amjpathol.org>). The estimated parameter values of this specification are presented in supplemental Table S3 (at <http://ajp.amjpathol.org>). The control group is heterogeneous (parameter $\sigma^2 \neq 0$). The group of rapamycin-treated mice has slightly increased baseline hazard compared with the control group (parameters $\alpha > 0$, $\beta > 0$). The experimental group is frailer on average ($r > 1$) and more heterogeneous ($\gamma > 1$), compared with the control group.

Results

Treatment with rapamycin significantly inhibited age-related weight gain (Figure 1A). Whereas control mice constantly gained weight during their lifespan, mice that received rapamycin demonstrated a very modest weight

Table 2. Effect of Rapamycin on Parameters of Lifespan in Female HER-2/neu Mice

Parameters	Control	Rapamycin
Number of mice	28	30
Mean lifespan (M $\pm$ SE), days	296 $\pm$ 5.9	308 $\pm$ 12.9 (+4.1%)
Median	288	327 (+13.6%)
Mean lifespan of last 10% survivors, days	356 $\pm$ 4.3	395 $\pm$ 6.9 (+11.0%) [†]
Maximum lifespan, days	362	407 (+12.4%)
Aging rate α (days ⁻²) [‡]	3.02 (3.01; 3.21)	1.67* (1.64; 1.76) –1.8 times
MRDT, days [§]	23.0 (21.6; 23.0)	41.6* (39.4; 42.3) +1.8 times

The difference with controls is significant, * $P < 0.05$; [†] $P < 0.01$.

[‡]Parameter α in the Gompertz equation $R = R_0(\exp) \alpha t$, where R_0 = mortality at $t_0 = 150$.

[§]MRDT, mortality rate doubling time, days (95% confidence limits are given in parentheses).

Figure 2. Suppression of carcinogenesis by rapamycin. **A:** Effect of rapamycin on tumor yield curves in female transgenic HER-2/neu mice. **B:** Effect of rapamycin on cumulative number of tumors in female transgenic HER-2/neu mice. **C:** Effect of rapamycin on distribution of mice with multiple mammary tumors in female transgenic HER-2/neu mice. Asterisks mean that according to the Fisher exact test for count data the distributions of the number of mice bearing 1 to 4, 5 to 7, and 8 to 10 tumors is significant with $P = 0.0006959$.

Table 3. Effect of Rapamycin on Development of Mammary Adenocarcinomas (MAC) in Transgenic HER-2/neu Mice

Parameters	Control	Rapamycin
Number of mice	28	30
Number of tumor-bearing mice, %	28 (100%)	23* (76.7%)
Mean latency of the first mammary adenocarcinoma, days	206 ± 3.3	240 ± 8.9 [†] (+16.5%)
Total number of mammary adenocarcinomas	233	126
Number of tumors per tumor-bearing mouse	8.3 ± 0.3	5.5 ± 0.6 [†] (-33.7%)
Mean size of MAC, cm ³	1.7 ± 0.04	1.3 ± 0.08 [†] (-23.5%)
Nos. of mice with MAC metastases into lungs, %	10 (37.0%)	12 (+52.2%)
Mean time of death of metastases-bearing mice	301 ± 10.9	357 ± 7.9 [†] (-18.6%)
Mean size of MAC, cm	0.5 ± 0.05	0.5 ± 0.06

The difference with controls is significant, * $P < 0.01$; [†] $P < 0.001$.

increase. As a result, for the period between 4 and 10 months, the weight of control animals increased by 62% and only by 17.5% in the group treated with rapamycin ($P > 0.05$; Figure 1A). Most importantly, in control group only 4 mice survived until 11 months (14.3%) compared with 13 animals (43.3%) in rapamycin-treated group ($P < 0.001$; Figure 1B and Table 1). Rapamycin treatment increased mean (+4.1%) and maximal lifespan (+12.4%; Table 2). Notably, the increase in mean lifespan was relatively modest because it was blunted by aging-independent mortality (Figure 1B, days 150 to 250). Mean lifespan of long-living animals (last 10% of survivors) was significantly greater in the group receiving rapamycin (+11%) compared with control. Parameter α of the Gompertz model, which is interpreted as the rate of aging, was 1.8 times lower in the group subjected to rapamycin treatment than in control. All differences between control and experimental groups were statistically significant (Table 2).

The kinetic of tumor incidence in rapamycin-treated mice was significantly slower than the kinetic in control animals (Figure 2, A and B). Thus, 50% of control mice developed mammary adenocarcinoma by day 206, whereas in rapamycin-treated group this period was extended to 240 days. Remarkably, rapamycin decreased the mean number of tumors per tumor-bearing mouse by 33.7% and the mean size of mammary adenocarcinoma by 23.5% (Table 3).

The number of tumors per animal was also significantly decreased by rapamycin. Thus, 75% of control mice were bearing from 8 to 10 tumors per mouse, whereas in the group treated with rapamycin only 30.4% of animals were bearing this number of mammary adenocarcinoma per animal (Figure 2C). In turn, only one control mouse developed fewer than four tumors, whereas in rapamycin-

cin-treated group, 10 of 23 mice (43.5%) developed one to four tumors (Figure 2C). These data demonstrate that rapamycin not only increased lifespan, but also reduced tumorigenesis in cancer-prone mice.

Discussion

Rapamycin delays tumor onset and progression in cancer-prone and carcinogen-treated rodents.^{25–29} In particular, five MMTV-c-Neu mice bearing tumors were treated with 150 μ g rapamycin (a dose approximately 3 times higher than the dose used in our study) for 32 days and tumor regression was observed.²⁹ However, the effect of rapamycin on longevity of cancer-prone mice has not been previously investigated. Theoretical considerations predict that rapamycin would slow down organismal aging.^{13,30} Here we show for the first time that rapamycin prolongs lifespan and decreases rate of aging in cancer-prone mice. Noteworthy, rapamycin failed to increase lifespan when given to mice with already established tumors, even though it decelerated tumor growth (data not shown). This suggests that rapamycin decreases tumorigenesis by slowing down aging rather than increases lifespan by decelerating cancer. In fact, effects of rapamycin are reminiscent of effects of CR, which both slows down the aging process and delays cancer.¹⁶ This resemblance is not accidental because both CR and rapamycin deactivate the nutrient-sensing mTOR pathway.⁸ There are several lines of evidence supporting the indirect mechanism of action of rapamycin on tumorigenesis. First, as we show here, rapamycin prevented age-related weight gain suggesting that, like CR, it may delay cancer by indirect mechanism. This prevention of weight gain was not attributable to toxic effects of rapamycin, because a short-term (32 days) administration of approximately threefold higher doses of rapamycin did not cause weight loss.²⁹ Second, consistent with indirect mechanism of action, rapamycin inhibited cancer growth in mice more profoundly than in cell culture.^{27,31} And third, similar to CR, rapamycin extends lifespan in a heterogeneous group of mice, which die from various diseases not necessarily related to cancer.¹⁴ In fact, rapamycin delays other age-related diseases such as atherosclerosis, metabolic disorders and neurodegeneration, organ fibrosis, age-related macular degeneration, and osteoarthritis.^{32–35} Taken together, these data support the notion that rapamycin decelerates age-related diseases by slowing down organismal aging. Similarly, CR and fasting can delay tumorigenesis in cancer-prone mice, including p53-deficient mice.³⁶ In addition, metformin, which mimics CR and inhibits mTOR via AMPK, prolongs lifespan²⁴ and delays cancer in cancer-prone mice.³⁷

Importantly, as we demonstrate here, rapamycin extends maximal lifespan even when administered intermittently (two consecutive weeks followed by a two-week break). This is a reminiscence of life extension and cancer prevention caused by intermittent CR. For example, fasting delays cancer in p53^{−/−} mice even if applied once a week and started late in life.³⁶ We suggest that slowing down the aging process caused by intermittent

administration of rapamycin would be beneficial for humans with high risk of cancer. This is especially important given that existing chemopreventive modalities have not demonstrated life extension.

Acknowledgment

We thank three anonymous reviewers for helpful comments and suggestions.

References

- Guarente L, Kenyon C: Genetic pathways that regulate ageing in model organisms. *Nature* 2000, 408:255–262
- Demidenko ZN, Blagosklonny MV: Growth stimulation leads to cellular senescence when the cell cycle is blocked. *Cell Cycle* 2008, 7:3355–3361
- Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F: Genetics: influence of TOR kinase on lifespan in *C. elegans*. *Nature* 2003, 426:620
- Jia K, Chen D, Riddle DL: The TOR pathway interacts with the insulin signaling pathway to regulate *C. elegans* larval development, metabolism and life span. *Development* 2004, 131:3897–3906
- Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S: Regulation of lifespan in *Drosophila* by modulation of genes in the TOR signaling pathway. *Curr Biol* 2004, 14:885–890
- Bartke A: Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. *Trends Endocrinol Metab* 2006, 17:33–35
- Wullschlegel S, Loewith R, Hall MN: TOR signaling in growth and metabolism. *Cell* 2006, 124:471–484
- Jiang W, Zhu Z, Thompson HJ: Dietary energy restriction modulates the activity of AMP-activated protein kinase. Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. *Cancer Res* 2008, 68:5492–5499
- Bordone L, Guarente L: Calorie restriction. SIRT1 and metabolism: understanding longevity. *Nat Rev Mol Cell Biol* 2005, 6:298–305
- Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weinbruch R: Caloric restriction delays disease onset and mortality in rhesus monkeys. *Science* 2009, 325:201–204
- Kaeberlein M, Powers RW, KKS, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S, Kennedy BK: Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. *Science* 2005, 310:1193–1196
- Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV: Rapamycin decelerates cellular senescence. *Cell Cycle* 2009, 8:1888–1895
- Blagosklonny MV: An anti-aging drug today: from senescence-promoting genes to anti-aging pill. *Drug Disc Today* 2007, 12:218–224
- Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009, 460:392–396
- DePinho RA: The age of cancer. *Nature* 2000, 408:248–254
- Anisimov VN: Biology of aging and cancer. *Cancer Control* 2007, 14:23–31
- Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A: Delayed occurrence of fatal neoplastic diseases in ams dwarf mice: correlation to extended longevity. *J Gerontol A Biol Sci Med Sci* 2003, 58:291–296
- Ikeno Y, Hubbard GB, Lee S, Cortez LA, Lew CM, Webb CR, Berryman DE, List EO, Kopchick JJ, Bartke A: Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. *J Gerontol A Biol Sci Med Sci* 2009, 64:522–529
- Cowey S, Hardy RW: The metabolic syndrome: a high-risk state for cancer? *Am J Pathol* 2006, 169:1505–1522
- Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM: Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. *Cancer Res* 1997, 57:2843–2846

21. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC: Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. *Annu Rev Med* 2003, 54:131–152
22. Caruso C, Lio D, Cavallone L, Franceschi C: Aging, longevity, inflammation, and cancer. *Ann N Y Acad Sci* 2004, 1028:1–13
23. Anisimov VN, Popovich IG, Zabezhinski MA: Methods of evaluating the effect of pharmacological drugs on aging and life span in mice. *Methods Mol Biol* 2007, 371:227–236
24. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV: Metformin slows down aging and extends life span of female SHR mice. *Cell Cycle* 2008, 7:2769–2773
25. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. *Cancer Res* 2007, 67:2408–2413
26. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA: Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. *Clin Cancer Res* 2007, 13:2281–2289
27. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD, Gregg JP: Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. *Clin Cancer Res* 2006, 12:2613–2621
28. Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A: Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. *J Pathol* 2009, 219:35–40
29. Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA: Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. *Mol Cancer Ther* 2007, 6:2188–2197
30. Blagosklonny MV: Prevention of cancer by inhibiting aging. *Cancer Biol Ther* 2008, 7:1520–1524
31. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, Abraham RT: Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. *Cancer Res* 2005, 65:5325–5336
32. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 2005, 37:19–24
33. Tee AR, Blenis J: mTOR, translational control and human disease. *Semin Cell Dev Biol* 2005, 16:29–37
34. Tsang CK, Qi H, Liu LF, Zheng XFS: Targeting mammalian target of rapamycin (mTOR) for health and diseases. *Drug Disc Today* 2007, 12:112–124
35. Blagosklonny MV: Validation of anti-aging drugs by treating age-related diseases. *Aging* 2009, 1:281–288
36. Berrigan D, Perkins SN, Haines DC, Hursting SD: Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. *Carcinogenesis* 2002, 23:817–822
37. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Exp Gerontol* 2005, 40:685–693